All In Biotech

Drug Trial Radar · NCT06809218

A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol

INSPiRE-ICU 1 & 2: A Pooled Analysis of Long-Term Outcomes at 3 and 6 Months After Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients

Last checked: Nov 20, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Apr 22, 2022

Primary completion

Nov 14, 2024

Study completion Jan 30, 2025

Sponsor

Lead sponsor
Sedana MedicalIndustry
Sponsor type
Industry
Collaborators
Critical Illness, Brain Dysfunction, and Survivorship Center
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pooled analysis will assess Cognitive, Mental Health, Functioning, and Quality of Life Assessments data from the Phase 3 registration studies INSPiRE-ICU 1 (NCT05312385) and INSPiRE-ICU 2 (NCT05327296) to explore potential differences in Long-Term Outcomes at 3 and 6 months after treatment between critically ill mechanically ventilated patients sedated with inhaled isoflurane compared to sedated with intravenous propofol. The analyses were pre-planned and agreed prior to completion of enrollment of either study.

Conditions

  • Post-Intensive Care Syndrome
  • Sedation

Interventions

  • Inhaled isoflurane administered by Sedaconda ACD-SDrug

    Intervention: isoflurane

  • Intravenous infusion of propofolDrug

    Intervention: propofol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare cognitive function 3 months post randomization in isoflurane- vs propofol-treated patientsTime frame: 3 months post Randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Critical Illness, Brain Dysfunction and Survivorship (CIBS) Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.